Guangzhou Wondfo Biotech News

Wanfu Biotech (300482): Restorative growth in conventional domestic business and continued breakthroughs in overseas layout

海通證券May 11 11:00

Wanfu Biotech (300482): New product registration and further expansion of application scenarios in the next city

華泰證券May 4 11:00

Wanfu Biotech (300482) Commentary on important matters: Respiratory Trilateral Testing FDA certification is expected to increase performance

華創證券Apr 24 05:11

Wanfu Biotech (300482): Continued increase in profitability, diversified layout helps high-quality growth

信達證券Apr 23 22:26

Cinda Securities released a research report on April 24 stating that it gave Wanfu Biotech (300482.SZ) a purchase rating. The main reasons for the rating include: 1) regular business continues to grow, and profitability continues to increase; 2) strengthe

Zhitong FinanceApr 23 20:00

Wanfu Biotech (300482): Strong growth in conventional business, the approval of the Joint Inspection Service in the US has exceeded expectations

銀河證券Apr 23 18:16

Wanfu Biotech (300482): Regular business continued to resume for 23 years, concurrent regular/special projects

廣發證券Apr 22 03:26

Wanfu Biotech (300482): Major new product approved, optimistic about subsequent performance

華泰證券Apr 21 11:00

Wanfu Biology (300482): Focus on in vitro diagnosis POCT to create domestic and international dual cycles

西南證券Apr 6 11:00

Wanfu Biotech (300482) 2023 Third Quarter Report Review: Steady Growth in Domestic Business and Continued Implementation of Overseas New Technology Platforms

華創證券Nov 1, 2023 18:22

Wanfu Biotech (300482): Continuously Deepening Overseas Layout Innovation to Drive Future Growth

銀河證券Oct 26, 2023 11:00

Wanfu Biotech (300482): Optimistic about the company's new product development and strategic breakthroughs

廣發證券Oct 26, 2023 03:12

Wanfu Biotech (300482): Continued overseas deepening of domestic production lines has significant advantages

國金證券Oct 24, 2023 11:00

Wanfu Biotech (300482): The COVID-19 base has been digested and the international market is gradually entering the harvest period

信達證券Oct 18, 2023 11:00

Wanfu Biotech (300482): Regular business growth is strong, new platforms, and new projects have achieved breakthroughs

海通證券Aug 26, 2023 11:00

Wanfu Biotech (300482) 2023 Interim Report Review: Regular Business Growth Is Good, and International Layout Continues to Advance

中信證券Aug 18, 2023 00:51

Wanfu Biotech (300482) 2023 Semi-Annual Report Review: Regular Business Achieves High Resilience Growth, Four Major Business Lines Accumulated and Underdeveloped

華創證券Aug 17, 2023 06:56

Wanfu Biotech (300482): Regular business resumes rapid growth

廣發證券Aug 16, 2023 11:00

Wanfu Biotech (300482): Regular business recovery is good, POCT's full technology platform layout leads future growth

銀河證券Aug 14, 2023 11:00

Wanfu Biotech (300482) Investment Value Analysis Report: POCT is on the rise and the leader is already over the top of the mountain

中信證券Jul 8, 2023 11:00